Trublood™ is a no-risk Biopsy. A Simple Blood Test for Cancer Diagnosis. It Could Save Your Life.

Patients with suspicious findings such as externally visible lumps on the body or in whom medical imaging (endoscopy, CT, MRI or USG) detected an abnormal growth (‘tumor’) may raise suspicions of cancer. Depending on where the suspicious finding is located in the body, about 50% – 80% of these tumors may actually be non-cancerous (benign) and without significant health risks.

However, confirming this (cancer v/s benign) requires a sample of the tumor tissue to be tested by ‘histopathological examination’ (HPE). Obtaining this tissue sample can be achieved through either surgical intervention or a biopsy, both of which are invasive procedures requiring an incision (cut) made in the skin with a scalpel to extract a portion of the suspicious tissue from within the body.

Tissue sampling is associated with risks such as pain, soreness, bleeding and infection. In certain cases, particularly for organs such as the lungs or brain, these risks may be even more significant. Sometimes, tissue sampling may not be possible because of these risks. In some cases, insufficient tissue sample may lead to a dilemma due to inconclusive findings. In the cases where these problems are encountered, a repeat tissue sampling procedure may be considered but may not always be possible.

Custom icon

About Trublood™

Trublood™ represents an advanced and innovative, minimally invasive test that offers valuable diagnostic insights into cancer through a safe, simple, and quick blood draw. Trublood™ was developed by Datar Cancer Genetics based on the results of several clinical studies and validated on more than 40,000 samples. These included samples from asymptomatic subjects undergoing screening tests such as mammograms, colonoscopies, PAP smears, serum CA markers and other clinical examinations, as well as more than 17,000 samples from patients with various cancers and patients with benign diseases.

Trublood™ can provide accurate, reliable, and diagnostically relevant information, which can assist physicians to make life-saving diagnostic and clinical management decisions more effectively.

How does
Trublood™ work?

Trublood™ assesses a blood sample to detect 'Circulating Tumor Cells' (CTCs), which are cancer cells that escape from the tumor and enter the bloodstream. Trucheck™ enriches and confirms the identity of these CTCs through a process called Immunocytochemistry (ICC). A positive CTC finding is an indicator of the presence of cancer, while the absence of detectable CTCs suggests that the patient may not have cancer.

Trublood™ Basics

  • Tumours release thousands of cells into the circulation, where circulating tumour cells (CTCs) survive for about 1 – 2.5 hours.
  • In order to detach from the primary tumour and disseminate into the blood, cells must undergo a cellular process known as Epithelial Mesenchymal Transition (EMT).
  • EMT enhances migratory capabilities of tumour cells, which allows cells to penetrate into the vasculature and circulate as single or clusters of circulating tumour cells.
  • CTCs extravasate having undergone the reverse process known as Mesenchymal to Epithelial Transition (MET) and are able to colonise at distant organs.
  • CTCs are defined as EpCAM (+), PanCK (+), CD45 (-) cells. Circulating tumour associated cells (C-TACs) are EpCAM (+), PanCK (+), CD45 (+/-) cells of tumourigenic origin in peripheral blood.
  • Non-tumourigenic cells in peripheral blood have functional apoptotic mechanism, but CTCs and C-TACs are resistant to apoptosis.
  • An epigenetically active stabilising process can eliminate normal cells and confer survival privilege on apoptosis-resistant CTCs and C-TACs.
  • Sufficient C-TACs can be enriched and harvested for immunocytochemistry (ICC) profiling with markers used in immunohisto-chemistry (IHC) which aid in determination of histopathological subtypes of tumour tissue.
  • Antibody clones used in the trublood assay for analysis of tumour antigens / markers are internationally approved for IVD use.

Clinical Performance

Trublood™ has been developed and validated by analysis of more than 40,000 samples in large cohort studies. Trublood™ has >99% Accuracy for the detection and localization of cancers.

A prescription blood test that can help diagnose cancers based on detection of organ specific Circulating Tumor Cells (CTCs).

• Patients who have been advised a biopsy to rule out suspected cancer. • Patients in whom a recent biopsy has been inconclusive. • Patients in whom a biopsy is not feasible. • Patients who are suspected of cancer recurrence.

Custom icon
How it Works?

Circulating tumor cells are isolated from a patient’s blood sample and extensively analyzed to assist in the diagnosis of cancer.

Custom icon
Why should I get Checked?

Invasive biopsies are expensive, risk-prone procedures. Many patients who undergo a biopsy are diagnosed with benign conditions. Trublood™, which requires only a simple blood draw, can reduce the need for biopsies in patients with benign conditions.

Trublood™ Brochures

Trublood™ has been developed and validated by analysis of more than 40,000 samples in large cohort studies. Trublood™ has >99% Accuracy for the detection and localization of cancers. Trublood™ is currently available for the following cancer types, download some of the brochures below:

Trublood – Prostate
Trublood – Bladder Cancer
Trublood – Breast Cancer
Trublood – Cervical Cancer

Trublood – Colorectum Cancer
Trublood – Esophagus Cancer
Trublood – Gallbladder Cancer
Trublood – Head & Neck Cancer

Trublood – Kidney Cancer
Trublood – Liver Cancer
Trublood – Lung Cancer
Trublood – Ovary Cancer

Trublood – Pancreas Cancer
Trublood – Stomach Cancer
Trublood – Thyroid Cancer
Trublood – Uterine Cancer

A Comparison
Usual Tissue Biopsy V Trublood™

Usual Tissue Biopsy / FNAC

  • Invasive, need of tissue
  • Usually painful, possible stitches and scars
  • Risk of tumour cell seeding
  • Risky procedure for organs like lung, liver, pancreas
  • Possibly misleading as it is site / time dependent
  • Serial / sequential biopsies are impossible
  • Not viable if primary tumor is not easily visualised
  • Minimally invasive
  • No pain, no stitches, no scars; only one blood draw
  • No risk
  • No risk of injury to any organ / bleeding
  • Provides real time data and covers all active sites
  • Can be performed as often as necessary
  • Viable even if primary / metastasis are undetectable

Sample Collection

  • Basic diagnostics (total 3 tubes containing 26 ml whole blood)
  • Blood draw: 3 EDTA tubes (purple colour cap) – 2 x 10 ml and 1 x 6 ml – in total: 26 ml
  • Basic diagnostics + cfDNA (trublood Comprehensive)
    (total 4 tubes containing 36 ml whole blood)
  • First draw : 10 ml DCG tube (brown colour cap)
  • Second draw: 3 x EDTA tubes (purple colour cap) – 2 x 10 ml and 1 x 6 ml – in total: 26 ml

    Sequence of draw should not be altered. Blood should be drawn only and only as per above method. Blood draw should be performed only by qualified phlebotomist under medical supervision. Ship at +2°C to +6°C in the container provided by DCG.


  • The patient must not have received any form of cancer therapy (radiation / chemo-therapy / surgery / endocrine therapy etc.) at least 15 days prior to collection of sample.
  • The patient must not have received oral or IV corticosteroids at least 15 days prior to collection of sample.
  • Patient has no current febrile or any other acute inflammatory illness.
  • Patient does not have acute exacerbation or flare-up of an inflammatory condition requiring escalation in medical therapy at least 5 days prior to collection of sample.
  • Patient has not received blood transfusion / PET-CT / CT scan at least 5 days prior to collection of sample.
  • Patient is not positive for HIV / HBV / HCV.

Important Publications

Accurate Prostate Cancer Detection Based On Enrichment And Characterization Of Prostate Cancer Specific Circulating Tumor Cells


Author: Limaye S
Datar Cancer Genetics
Posted on: Jan 30, 2023

Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells


Author: Crook T
Datar Cancer Genetics
Published Date: Jul 9, 2022

Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk.


Author: Ranade A
Datar Cancer Genetics
Published Date: Jan. 6, 2021

Accurate Identification of Glial Malignancies from Peripheral Blood


Author: Giulio Anichini
Imperial College London, London, England, United Kingdom
Published Date: Nov 14, 2022

Detection of Circulating Glial Cells Enables Non-Invasive Diagnosis of Glial Malignancies


Author: O’Neill K
Datar Cancer Genetics
Posted on: Jul 10, 2022

Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging.


Author: Gaya A
Datar Cancer Genetics
Published Date: Sept 30, 2020

Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer


Author: Akolkar D
Datar Cancer Genetics
Published Date: Nov 30, 2019


Although Trublood detects CTCs with high accuracy, it is intended for use only in patients with clinical or radiological findings suspected of cancer. DCG has other tests which facilitate cancer detection in asymptomatic individuals (screening).

Trublood is a ‘Prescription Only’ test that can be ordered by a qualified and licensed medical practitioner (physician) for their patients.

While Trublood findings can facilitate more effective diagnosis of cancers in cases, it is not a replacement for standard diagnostic procedures. Trublood findings must be interpreted and used by a qualified and licensed medical practitioner in conjunction with other relevant clinical evidence and assessments for establishing a final diagnosis.

A ‘Positive’ report should be followed by immediate consultation with a physician for appropriate guidance and additional Standard of Care work up as may be advised.

For those with a ‘Negative’ test report, the appropriate further steps would be decided by the treating physician.

Stay up to date for our

Latest News